Microdosing is a marketing word before it is a medical one. In the GLP-1 conversation it usually describes using an amount smaller than what a drug's label describes. That framing raises real questions about legality, sourcing, and cost, and those are the parts you can actually check before you commit to a provider.
What drugs are actually being discussed
The GLP-1 category most often marketed this way includes semaglutide and tirzepatide. A newer compound, retatrutide, also appears in these conversations. The regulatory picture is not the same for each, and that difference matters more than any dosing label a clinic puts on its website.
Semaglutide and tirzepatide are FDA approved as brand-name products for specific uses. Retatrutide is investigational. It is not FDA approved and it is not legally compoundable. Any provider offering it as a finished treatment is a reason to stop and ask questions.
Where the term gets legally complicated
Using less of an approved drug than the label suggests is a decision a licensed clinician can make for a patient. That is different from a compounding pharmacy producing a lower-strength version and marketing it under a new name. Compounding in the United States happens under 503A and 503B rules, and those rules turn on drug shortages, patient-specific need, and the identity of the ingredients.
When a branded GLP-1 is not on the FDA shortage list, the legal basis for compounding a copy narrows considerably. A provider using the word microdosing to sell a compounded product should be able to explain, in plain terms, what they are dispensing and under what authority.
How it can be legitimately available
The clean path is straightforward. A licensed clinician evaluates you, writes a prescription, and a licensed pharmacy fills it. That may be a brand-name product or, where permitted, a compounded preparation from a registered pharmacy. Research-use-only vendors are not a purchase channel. Products labeled that way are not intended for human use, and buying from them removes every protection a prescription and a licensed pharmacy provide.
What drives the cost
Price depends on the drug, the form, and the pharmacy. Brand-name approved products carry one set of prices, often shaped by insurance coverage or the lack of it. Compounded preparations are priced differently and vary by pharmacy. A smaller labeled amount does not automatically mean a smaller bill, because the same clinical oversight, shipping, and pharmacy handling still apply. Be skeptical of pricing that seems to undercut everyone else without a clear explanation.
How to vet a provider
Focus on verifiable facts rather than the language on the landing page.
- Ask which specific drug you would receive and whether it is FDA approved or compounded.
- Confirm the dispensing pharmacy is licensed and, for compounding, whether it operates under 503A or 503B.
- Ask how a licensed clinician evaluates you and remains reachable for follow-up.
- Watch for claims of guaranteed results, since no legitimate provider can promise outcomes.
If a clinic leans on the word microdosing but cannot answer these questions clearly, that is information in itself. The value of a directory like this one is comparison across licensed options, not a shortcut around the questions worth asking.